ArticleThe American journal of pathology2002
Interferon-gamma augments CD95(APO-1/Fas) and pro-caspase-8 expression and sensitizes human vascular endothelial cells to CD95-mediated apoptosis.
Article in The American journal of pathology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 65 citations in OpenAlex.
- Trial
- The Fas-FasL system: from apoptosis regulator to therapeutic target in autoimmunity, cancer, and transplantation.Immunologic research · 2026Review
- JAKinibs prevent persistent, IFNγ-autonomous endothelial cell inflammation and immunogenicity.American journal of physiology. Cell physiology · 2023Article
- Safe eradication of large established tumors using neovasculature-targeted tumor necrosis factor-based therapies.EMBO molecular medicine · 2020Article
- Ameliorative effects of selenium on the excess apoptosis of the jejunum caused by AFBToxicology research · 2018Article
- Therapeutic blockade of CD54 attenuates pulmonary barrier damage in T cell-induced acute lung injury.American journal of physiology. Lung cellular and molecular physiology · 2017Article
- Interferon Gamma Induces Changes in Natural Killer (NK) Cell Ligand Expression and Alters NK Cell-Mediated Lysis of Pediatric Cancer Cell Lines.Frontiers in immunology · 2017Article
- NF-κB signalling and cell fate decisions in response to a short pulse of tumour necrosis factor.Scientific reports · 2016Article
- Cold-inducible RNA-binding protein causes endothelial dysfunction via activation of Nlrp3 inflammasome.Scientific reports · 2016Article
- Graft microvascular disease in solid organ transplantation.Journal of molecular medicine (Berlin, Germany) · 2014Review
- Immune-mediated vascular injury and dysfunction in transplant arteriosclerosis.Frontiers in immunology · 2014Review
- The effect of interferon γ on endothelial cell nitric oxide production and apoptosis.Advanced biomedical research · 2012Article
- Pharmacological modulation of cell death in atherosclerosis: a promising approach towards plaque stabilization?British journal of pharmacology · 2011Review
- CD4+ regulatory T cells generated in vitro with IFN-{gamma} and allogeneic APC inhibit transplant arteriosclerosis.The American journal of pathology · 2010Article
- Lipopolysaccharide can trigger a cathepsin B-dependent programmed death response in human endothelial cells.The American journal of pathology · 2009Article
- Cardiovascular inflammation and lesion cell apoptosis: a novel connection via the interferon-inducible immunoproteasome.Arteriosclerosis, thrombosis, and vascular biology · 2009Article
- Endothelial cells in allograft rejection.Transplantation · 2008Review
- Angiogenesis in a human neuroblastoma xenograft model: mechanisms and inhibition by tumour-derived interferon-gamma.British journal of cancer · 2006Article
- ANG II induces apoptosis of human vascular smooth muscle via extrinsic pathway involving inhibition of Akt phosphorylation and increased FasL expression.American journal of physiology. Heart and circulatory physiology · 2006Article
- Sensitization of interferon-gamma induced apoptosis in human osteosarcoma cells by extracellular S100A4.BMC cancer · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
We have examined the effects of interferon (IFN)-gamma on expression and function of CD95 (APO-1/Fas) and associated proteins in cultured human umbilical vein and dermal microvascular endothelial cells (HUVEC and HDMEC, respectively). Unstimulated cells express only low levels of CD95; IFN-gamma produces a time- and concentration-dependent increase of CD95 in both cell types at the mRNA and cell surface protein levels. IFN-gamma also produces an increase in expression of pro-caspase-8 (FLICE/MACH) but does not significantly change expression of either Fas-associated death domain (FADD) protein or cellular FLICE inhibitory protein (cFLIP), other proteins associated with the CD95 death-inducing signaling complex (DISC). Neither resting nor IFN-gamma-treated EC express detectable CD95L mRNA or protein. Untreated HUVEC and HDMEC show minimal apoptosis when transduced to express CD95L. Treatment of CD95L-transduced cells with IFN-gamma causes apoptosis within 24 to 36 hours that can be blocked by antagonistic anti-CD95 antibody or by the caspase-inhibitory peptide zVAD-FMK. The extent of apoptosis is increased by co-treatment with either the protein synthesis inhibitor cycloheximide or the phosphatidylinositol 3-kinase inhibitor LY294002. Untransduced HUVEC treated with IFN-gamma also undergo CD95-initiated apoptosis when mixed with CD95L-transduced HUVEC or when incubated with pharmacologically activated cytolytic T lymphocytes. Overexpression of CD95 in HUVEC confers sensitivity to CD95L in the absence of IFN-gamma-treatment. We conclude that IFN-gamma induces sensitivity of endothelium to CD95L-mediated apoptosis, and that this response may result from increased expression of CD95 and/or pro-caspase-8.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.